Spouting Rock Asset Management’s CRISPR Therapeutics CRSP Stock Holding History

Spouting Rock Asset Management’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	$627K	Hold	10,008	–	–	0.23%	76
2023 Q3	$454K	Sell	10,008 -4,289	-30%	-$222K	0.15%	97
2023 Q2	$803K	Hold	14,297	–	–	0.29%	76
2023 Q1	$647K	Hold	14,297	–	–	0.23%	82
2022 Q4	$581K	Hold	14,297	–	–	0.43%	72
2022 Q3	$934K	Sell	14,297 -6,375	-31%	-$462K	0.72%	54
2022 Q2	$1.26M	Hold	20,672	–	–	0.82%	45
2022 Q1	$1.3M	Buy	+20,672	New	+$1.3M	1.08%	34

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Spouting Rock Asset Management's CRSP Position: Q4 2023 in Review

Spouting Rock Asset Management held its CRISPR Therapeutics (CRSP) position steady in Q4 2023 at 10,008 shares worth $627K. The position accounts for 0.23% of the portfolio, ranked #76.

Spouting Rock Asset Management first reported a position in CRSP in Q1 2022 and has held it in 8 quarters since. The position peaked at $1.3M in Q1 2022. 472 funds tracked by Wall St. Rank hold CRSP as of Q4 2023.

Spouting Rock Asset Management held 10,008 shares of CRISPR Therapeutics worth $627K as of Q4 2023.
Spouting Rock Asset Management left its CRISPR Therapeutics share count unchanged in Q4 2023.
CRISPR Therapeutics made up 0.23% of Spouting Rock Asset Management's portfolio in Q4 2023, its #76 holding.
Spouting Rock Asset Management first reported a position in CRISPR Therapeutics in Q1 2022 and has held it in 8 quarters since.
Spouting Rock Asset Management's CRISPR Therapeutics position peaked at $1.3M in Q1 2022.
472 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2023.

Based on Spouting Rock Asset Management's 13F filing for Q4 2023, filed 16 Feb 2024.